Additionally, the combined polymorphisms in PNPLA3 and SAMM50—specifically four SNPs—have been linked to an increased risk of MASLD and elevated serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels, suggesting more severe hepatic injury (109). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.